<DOC>
	<DOCNO>NCT01296763</DOCNO>
	<brief_summary>Patients whose pancreatic cancer defect BRCA/Fanconi DNA repair pathway defect homologous repair cancer respond olaparib give combination DNA damaging agent , irinotecan , cisplatin , mitomycin C ( ICM ) .</brief_summary>
	<brief_title>Trial ICM With Without AZD2281 ( Olaparib ) Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>The trial design evaluate role Parp inhibitor base therapy , combine well study potent Parp inhibitor currently available low-dose combination DNA damaging agent optimize effect Parp inhibition . To ensure optimal response rate trial , enrich population patient likely achieve best clinical response Parp inhibitor base therapy , recruit enroll patient know BRCA mutation , patient Jewish ancestry , patient familial pancreatic cancer , well sporadic pancreatic cancer . We test patient cancer inherit acquired defect homologous DNA repair . For phase 1 study , enroll 30 patient . For phase 2 component study , 100 patient locally , advance , unresectable metastatic pancreatic cancer enrol . An initial phase I analysis perform test safety ICM Olaparib regimen dose predict effective phase 2 ensure dos maximum tolerate dose . For phase 1 use standard 3+3 design test follow dose regimen 28 day cycle : Dose level 1 : Cisplatin/Irinotecan i.v . ( day 1 , 8 ) Olaparib ( 100 mg bid p.o. , Day 1 &amp; Day 8 ) Dose level 2 : Cisplatin/Irinotecan i.v . ( day 1 , 8 ) Olaparib 100 bid p.o . day 1-3 , day 8-10 ( dose tolerate , go Dose 5 : Mitomycin + Olaparib Dose level 1 ) Dose level 3 : Cisplatin/Irinotecan i.v . ( day 1 , 8 ) Olaparib 200 bid p.o.day 1-3 , day 8-10 ( dose tolerate , go Dose 5 : Mitomycin + Olaparib Dose level 2 ) Dose level 4 : Cisplatin/Irinotecan i.v . ( day 1 , 8 ) Olaparib 200 bid p.o . day 1-12 ( dose tolerate , go Dose 5 : Mitomycin + Olaparib Dose level 3 ) ) Dose level 5 : Cisplatin/Irinotecan i.v . ( day 1 , 8 ) , Mitomycin Day 1 ( 5 mg/m2 IV ) , along establish tolerate dose level Olaparib . Other intermediate dose schedule Olaparib may consider achieve optimal tolerable regimen '' If DLTs Dose 1 , reduce duration Olaparib Note : The Principal Investigator Astrazeneca decide move forward Phase II part study . Therefore arm Irinotecan , Cisplatin , Mitomycin C Olaparib versus Irinotecan , Cisplatin , Mitomycin C without Olaparib compare .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>1 . Provision fully inform consent prior study specific procedure . 2 . Histologic cytologic confirmation exocrine pancreatic adenocarcinoma . 3 . Locally advanced , inoperable ( due venous arterial encasement ≥ 180° vessel ) , and/or metastatic disease imaging ( CT , MRI , EUS ) . Acquisition tissue rather cytology encourage patient give informed consent . 4 . Measurable disease accord RECIST 1.1 criterion 5 . Prior neoadjuvant adjuvant therapy acceptable , long one drug ICM regimen use . 6 . No prior chemotherapy advance pancreatic cancer Olaparib permit . Gemzar , Tarceva , 5FU Xeloda , Oxaliplatin Taxotere , FOLFIRINOX permit . 7 . Three week since last surgery chemotherapy mention # 5 investigational therapy . Four week since radiation . 8 . No prior PARP inhibitor type 9 . ECOG status &lt; 3 10 . Life expectancy &gt; 3 month 11 . Patients must normal organ bone marrow function 12 . Age &gt; =18 . 13 . Patient willing able comply protocol duration study include treatment , schedule visit , examination . 14 . Evidence nonchildbearing status woman childbearing potential , postmenopausal status : negative urine serum pregnancy test within 28 day study treatment , confirm prior treatment day 1 For inclusion genetic research , patient must fulfill follow criterion : 15 . Provision inform consent genetic research . If patient decline participate genetic research , penalty loss benefit patient . The patient exclude aspect study . 1 . Patients second primary cancer , except : adequately treat nonmelanoma skin cancer curatively treat insitu solid tumor evidence disease ≥ 5 year . 2 . Patients receive systemic chemotherapy , radiotherapy ( except palliative reason ) , less 3 week last dose prior study treatment ( long period depend defined characteristic agent use ) . The patient receive stable dose bisphosphonates bone metastasis study long start least 4 week prior treatment . 3 . For patient locally advanced pancreatic cancer , receive therapeutic dos radiation therapy pancreatic bed ( ~50 Gy ) treatment locally advance pancreatic cancer 4 . Patients already prior chemotherapy 12 month advanced pancreatic cancer ( include adjuvant/neoadjuvant ) 5 . Patients receive follow class inhibitor CYP3A4 ( see Section guideline wash period ) . 6 . Current use azole antifungal , macrolide antibiotic , protease inhibitor 7 . Unresolved toxicity ( &gt; CTCAE 4.0 grade 2 ) cause previous cancer therapy . 8 . Patients know brain metastasis . A scan confirm absence brain metastasis require unless initial examination reveals CNS sign disease . 9 . Major surgery le 3 week prior start study treatment patient must recover effect major surgery . 10 . Patients consider poor medical risk due serious , uncontrolled medical disorder , nonmalignant systemic disease , active , uncontrolled infection . Examples include , limited , uncontrolled ventricular arrhythmia , recent ( within 3 month ) myocardial infarction , uncontrolled major seizure disorder , unstable spinal cord compression , superior vena cava syndrome , psychiatric disorder prohibits obtain informed consent . 11 . Patients unable swallow oral medication patient gastrointestinal disorder likely interfere absorption study medication . 12 . Breast feed and/or pregnant woman . 13 . Immunocompromised patient , e.g. , patient know serologically positive human immunodeficiency virus ( HIV ) . 14 . Patients know active hepatic disease ( i.e. , Hepatitis B C ) . Patients know hypersensitivity Olaparib excipients product history severe allergic reaction platinums chemotherapy . 15 . Grade 2 neuropathy entry etiology , include diabetes ( view Cisplatin ) . 16 . Prior episode recurrent deep vein thrombosis Trousseau 's Syndrome unless patient successfully anticoagulated . If patient history clot suspect Trousseau 's syndrome anticoagulated , DDimer level check . If &gt; 3 x ULN , patient expect anticoagulated low molecular weight heparinoids ( i.e . Lovonox ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Irinotecan</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Mitomycin-C</keyword>
	<keyword>Olaparib</keyword>
	<keyword>AZD2281</keyword>
</DOC>